{"doi":"10.3349/ymj.2023.0285","title":"Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review","abstract":null,"journal":"Yonsei Medical Journal","year":2024,"id":629640,"datarank":0.3958585994422889,"base_score":2.639057329615259,"endowment":2.639057329615259,"self_citation_contribution":0.3958585994422889,"citation_network_contribution":0.0,"self_endowment_contribution":0.3958585994422889,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":758384,"name":"Jung Mi Park","orcid":"0000-0002-7556-5175","position":1,"is_corresponding":false},{"id":857359,"name":"Sang‐Hak Lee","orcid":"0000-0002-4535-3745","position":2,"is_corresponding":false},{"id":1630814,"name":"Yura Kang","orcid":"0000-0002-1961-8017","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review","abstract":"PURPOSE: There are few studies in the literature on the dosage of statin that equivalently reduces low-density lipoprotein cholesterol (LDL-C) compared to an ezetimibe combination and whether such regimens have differences in safety. We compared the lipid-modifying efficacy and safety of 5 mg rosuvastatin/10 mg ezetimibe to those of 20 mg rosuvastatin. MATERIALS AND METHODS: A literature search was conducted using the PubMed, EMBASE, Cochrane, Web of Sciences, and SCOPUS databases up to December 2021. Human studies investigating the two aforementioned regimens with a randomized controlled design were selected. Outcome variables included the percentage reduction in LDL-C and other lipid parameters and rates of composite adverse events (AEs), including muscle-related symptoms. A random-effects meta-analysis was performed after heterogeneity testing between studies. RESULTS: =0.02), whereas that of triglyceride reduction and high-density lipoprotein cholesterol elevation did not differ between the two groups. CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.","is_dataset_classified":null,"base_score":2.639057329615259,"endowment":2.639057329615259,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38154476","pmcid":"PMC10774651","openalex_id":"https://openalex.org/W4390020222","authors":[],"funders":[{"funder_name":"National Research Foundation of Korea","grant_id":"2022R1A2C1004946","title":null}],"total_grants":1,"fwci":1.3181,"citation_percentile":0.76088218,"influential_citations":0,"citation_trend":[{"year":2024,"count":5},{"year":2025,"count":6},{"year":2026,"count":2}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"http://eymj.org/Synapse/Data/PDFData/0069YMJ/ymj-65-19.pdf","host_type":"journal"},{"url":"http://eymj.org/Synapse/Data/PDFData/0069YMJ/ymj-65-19.pdf","host_type":"publisher"},{"url":"https://eymj.org/pdf/10.3349/ymj.2023.0285","host_type":"publisher"},{"url":"https://eymj.org/DOIx.php?id=10.3349/ymj.2023.0285","host_type":"publisher"},{"url":"https://doi.org/10.3349/ymj.2023.0285","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38154476","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10774651","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10774651/pdf/ymj-65-19.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC10774651","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10774651?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Lipoproteins and Cardiovascular Health","Cancer, Lipids, and Metabolism","Antiplatelet Therapy and Cardiovascular Diseases","Humans","Rosuvastatin Calcium","Ezetimibe","Cholesterol, LDL","Anticholesteremic Agents","Hypercholesterolemia","Drug Therapy, Combination","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Treatment Outcome"],"mesh_terms":["Rosuvastatin Calcium","Ezetimibe","Anticholesteremic Agents","Drug Therapy, Combination","Humans","Hypercholesterolemia","Cholesterol, LDL","Treatment Outcome","Hydroxymethylglutaryl-CoA Reductase Inhibitors"],"keywords":["Rosuvastatin","Ezetimibe","Medicine","Statin","Meta-analysis","Rosuvastatin Calcium","Pharmacology","Internal medicine","Drug therapy","Hypercholesterolemia","Preventive Medicine","Hydroxymethylglutary-coa Reductase Inhibitors"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Zero hunger"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T19:16:14.669264Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}